Expanded Access to Elezanumab

AbbVie

Status

Conditions: Acute Spinal Cord Injury (SCI)

Treatments: Drug: Elezanumab

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT04278235

C20-285 (Other Grant/Funding Number)

C20-203

C20-284 (Other Grant/Funding Number)

Details and patient eligibility

About

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Elezanumab prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Exclusion Criteria:

• There are other suitable treatment options.
• The participant qualifies for ongoing clinical trials.